NCT02209714View on ClinicalTrials.gov

Safety, Tolerability and Pharmacodynamics After Oral Administration of BIIF 1149 BS in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 1999

Primary Completion Date

February 29, 2000

Conditions
Healthy
Interventions
DRUG

BIIF 1149 BS

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02209714 - Safety, Tolerability and Pharmacodynamics After Oral Administration of BIIF 1149 BS in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter